SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549


                                    FORM 10-Q

(MARK ONE)

 X            QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
----
                         SECURITIES EXCHANGE ACT OF 1934
                FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2000


            TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                        FOR THE TRANSITION PERIOD FROM TO


                           COMMISSION FILE NO. 1-5439


                             DEL LABORATORIES, INC.
                             ----------------------
             (Exact name of registrant as specified in its charter)


            DELAWARE                                        13-1953103
-------------------------------                        --------------------
(State or other jurisdiction of                         (I.R.S. Employer
 incorporation or organization)                        Identification No.)


                    178 EAB PLAZA, UNIONDALE, NEW YORK 11556
                    ----------------------------------------
               (Address of principal executive offices) (Zip Code)


       Registrant's telephone number, including area code: (516) 844-2020

                            -------------------------


Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.

                              YES (X)         NO ( )

The number of shares of Common Stock, $1 par value, outstanding as of November
6, 2000 was 7,595,209.





<PAGE>





                     DEL LABORATORIES, INC. AND SUBSIDIARIES

                                      Index






Part I.      FINANCIAL INFORMATION
PAGE NO.

                                                                            PAGE

Item 1.      Financial Statements:

             Consolidated Balance Sheets as of
                September 30, 2000 and December 31, 1999                      3

             Consolidated Statements of Operations for the three and nine
                months ended September 30, 2000 and 1999                      4

             Consolidated Statements of Cash Flows for the
                nine months ended September 30, 2000 and 1999                 5

             Notes to Consolidated Financial Statements                       6

Item 2.      Management's Discussion and Analysis of Financial
             Condition and Results of Operations                             10


PART II.  OTHER INFORMATION

Item 6.     Exhibits and Reports on Form 8-K                                 13


SIGNATURES                                                                   14



All other schedules and compliance information called for by the instructions to
Form 10-Q have been omitted since the required information is not present or not
present in amounts sufficient to require submission.










                                       -2-


<PAGE>
<TABLE>
<CAPTION>


                       DEL LABORATORIES, INC. AND SUBSIDIARIES
                             CONSOLIDATED BALANCE SHEETS
                 (In thousands except for share and per share data)


                                                                   September 30    December 31
       ASSETS                                                         2000            1999
       ------                                                      ------------    -----------
                                                                   (UNAUDITED)
Current assets:
<S>                                                                 <C>          <C>
       Cash and cash equivalents                                    $   3,273    $   3,585
       Accounts receivable-less allowance for doubtful accounts
       of $1,300 in 2000 and 1999                                      58,253       45,942
       Income taxes receivable                                           --          1,963
       Inventories                                                     61,884       59,155
       Deferred income taxes, net                                       5,272        5,272
       Prepaid expenses and other current assets                        3,911        2,455
                                                                    ---------    ---------
            Total current assets                                      132,593      118,372

Property, plant and equipment, net                                     37,905       37,191
Intangibles arising from acquisitions, net                             16,440       17,101
Other assets                                                            8,835        7,897
                                                                    ---------    ---------
            Total assets                                            $ 195,773    $ 180,561
                                                                    =========    =========

       LIABILITIES AND SHAREHOLDERS' EQUITY

Current liabilities:
       Current portion of long-term debt                            $   4,120    $   3,888
       Accounts payable                                                28,443       27,175
       Accrued liabilities                                             16,044       12,837
       Income taxes payable                                               314         --
                                                                    ---------    ---------
            Total current liabilities                                  48,921       43,900

Long-term pension liability, less current portion                       9,052        9,052
Deferred income taxes, net                                                986          986
Long-term debt, less current portion                                   82,517       75,750
                                                                    ---------    ---------
            Total liabilities                                         141,476      129,688
                                                                    ---------    ---------
Shareholders' equity:
       Preferred stock $.01 par value, authorized
       1,000,000 shares; no shares issued                                --           --
       Common stock $1 par value, authorized
       20,000,000 shares; issued 10,000,000 shares                     10,000       10,000
       Additional paid-in capital                                        --            127
       Accumulated other comprehensive loss                            (1,260)      (1,029)
       Retained earnings                                               77,888       75,136
                                                                    ---------    ---------
                                                                       86,628       84,234
       Less:  Treasury stock at cost, 2,404,791 shares
       at September 30, 2000 and 2,455,420 at December 31, 1999       (31,236)     (32,120)
       Receivables for stock options exercised                         (1,095)      (1,241)
                                                                    ---------    ---------
           Total shareholders' equity                                  54,297       50,873
                                                                    ---------    ---------
            Total liabilities and shareholders' equity              $ 195,773    $ 180,561
                                                                    =========    =========

</TABLE>


               The accompanying notes are an integral part of the
                       consolidated financial statements.

                                       -3-


<PAGE>

<TABLE>
<CAPTION>

                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF OPERATIONS
         FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2000 AND 1999
               (In thousands except for share and per share data)
                                   (UNAUDITED)


                                            THREE MONTHS ENDED           NINE MONTHS ENDED
                                               SEPTEMBER 30                SEPTEMBER 30
                                               ------------                ------------
                                          2000            1999          2000           1999
                                          ----            ----          ----           ----

<S>                                   <C>            <C>            <C>            <C>
Net sales                             $    77,653    $    64,586    $   221,722    $   196,899

Cost of goods sold                         34,807         34,748         98,116         93,245
Selling and administrative expenses        38,649         37,289        111,552        106,900
                                      -----------    -----------    -----------    -----------
   Operating income (loss)                  4,197         (7,451)        12,054         (3,246)

Other income (expense):
   Gain on sale of facility                  --             --              362          1,734
   Interest expense                        (2,171)        (1,528)        (6,268)        (4,270)
   Interest income                            129             16            155             41
                                      -----------    -----------    -----------    -----------
Earnings (Loss) before income taxes         2,155         (8,963)         6,303         (5,741)
Income taxes expense (benefit)                981         (2,897)         2,723         (1,608)
                                      -----------    -----------    -----------    -----------
   Net earnings (loss)                $     1,174    $    (6,066)   $     3,580    $    (4,133)
                                      ===========    ===========    ===========    ===========

Earnings (Loss) per common share:
   Basic                              $      0.15    $     (0.81)   $      0.47    $     (0.55)
                                      ===========    ===========    ===========    ===========
   Diluted                            $      0.15    $     (0.81)   $      0.47    $     (0.55)
                                      ===========    ===========    ===========    ===========

Weighted average common
 shares outstanding:
   Basic                                7,576,000      7,503,000      7,555,000      7,534,000
                                      ===========    ===========    ===========    ===========
   Diluted                              7,652,000      7,503,000      7,639,000      7,534,000
                                      ===========    ===========    ===========    ===========








</TABLE>



               The accompanying notes are an integral part of the
                       consolidated financial statements.




                                       -4-


<PAGE>
<TABLE>
<CAPTION>


                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
              FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2000 AND 1999
                                 (In thousands)
                                   (UNAUDITED)

                                                                September 30
                                                                ------------

                                                              2000        1999
                                                              ----        ----

Cash flows from operating activities:
<S>                                                        <C>         <C>
Net earnings (loss)                                        $  3,580    $ (4,133)
Adjustments to reconcile net earnings (loss) to net cash
  provided by (used in) operating activities:
Depreciation and amortization                                 5,573       5,167
Provision for doubtful accounts                                  58          73
Gain on sale of facility                                       (362)     (1,734)
Other non-cash operating items                                  240         719
Changes in operating assets and liabilities:
    Accounts receivable                                     (12,473)        (87)
    Inventories                                              (2,906)     (6,242)
    Prepaid expenses and other current assets                (1,460)     (2,471)
    Other assets                                               (939)       (280)
    Accounts payable                                          1,336      (1,233)
    Accrued liabilities                                       3,234       1,825
    Income taxes payable / receivable                         2,888         (71)
                                                           --------    --------
          Net cash used in operating activities              (1,231)     (8,467)
                                                           --------    --------

Cash flows provided by (used in) investing activities:
    Proceeds from sale of facility                              800       2,538
    Property, plant and equipment additions                  (4,361)     (4,948)
    Additions to intangibles and other assets                  --            85
                                                           --------    --------
         Net cash used in investing activities               (3,561)     (2,325)
                                                           --------    --------

Cash flows provided by (used in) financing activities:
    Borrowings under long-term debt                          29,023       4,250
    Principal payments under long-term debt                  (8,086)       (329)
    Borrowings under short-term lines of credit               1,500      14,750
    Repayments of short-term lines of credit                (17,250)     (3,500)
    Decrease in receivables for stock options exercised           6           7
    Acquisition of treasury stock                              (696)     (4,539)
    Dividends paid                                             --        (1,037)
                                                           --------    --------
          Net cash provided by financing activities           4,497       9,602
                                                           --------    --------
Effect of exchange rate changes on cash                         (17)          8
                                                           --------    --------
Net decrease  in cash and cash equivalents                     (312)     (1,182)

Cash and cash equivalents at beginning of year                3,585       3,731
                                                           --------    --------
Cash and cash equivalents at end of period                 $  3,273    $  2,549
                                                           ========    ========
</TABLE>



                                       -5-


<PAGE>














                     DEL LABORATORIES, INC. AND SUBSIDIARIES
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS






  1.  SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
      ------------------------------------------

      The accompanying unaudited consolidated financial statements of Del
      Laboratories, Inc. and subsidiaries (the Company) have been prepared in
      accordance with generally accepted accounting principles for interim
      financial information and with the instructions to Form 10-Q. Accordingly,
      they do not include all of the information and footnotes required by
      generally accepted accounting principles for complete financial
      statements. Interim results are not necessarily indicative of results for
      a full year.

      A summary of the Company's significant accounting policies is presented in
      its 1999 Annual Report to Shareholders. Users of financial information
      produced for interim periods are encouraged to refer to the footnotes
      contained in the Annual Report to Shareholders when reviewing interim
      financial results.

      In the opinion of management, the accompanying interim financial
      statements contain all material adjustments, consisting only of normal
      recurring adjustments, necessary to present fairly the consolidated
      financial position, results of operations and cash flows of the Company
      for interim periods.



  2.  INVENTORY
      ---------

      Classification of inventories (in thousands):

                                September 30       December 31
                                        2000              1999
                                        ----              ----

          Raw Materials            $ 39,648         $  27,936
          Work In Process             5,145             6,226
          Finished Goods             17,091            24,993
                                  ---------         ---------
                                  $  61,884         $  59,155
                                  =========         =========



  3.  EARNINGS PER SHARE
      ------------------

      Basic earnings per share is computed by dividing income available to
      common shareholders (which for the Company equals its recorded net income)
      by the weighted-average number of common shares outstanding during the
      period. Diluted earnings per share reflects the potential dilution that
      could occur if securities or other contracts to issue common stock, such
      as stock options, were exercised, converted into common stock or otherwise
      resulted in the issuance of common stock.


      On November 15, 1999, the Company's Board of Directors approved a 2% stock
      dividend. As a result, 147,581 shares of treasury stock were issued on
      December 28, 1999 to shareholders of record on November 30, 1999.
      Accordingly, the weighted average common shares outstanding in the
      consolidated statement of operations for the three and nine months ended
      September 30, 1999, have been restated to reflect the dividend.









                                       -6-

<PAGE>






      3.   EARNINGS PER SHARE (CONTINUED)
           ------------------------------

      A reconciliation between the numerators and denominators of the basic and
      diluted earnings (loss) per common share is as follows:




                                         Three Months Ended    Nine Months Ended
                                           September 30          September 30
                                   (Amounts in thousands, except per share data)


                                          2000       1999       2000      1999
                                          ----       ----       ----      ----

    Net earnings (loss) (numerator)      $ 1,174   $(6,066)   $ 3,580   $(4,133)
                                         -------   -------    -------   -------




    Weighted-average common shares

       (denominator for basic earnings


       (loss) per share)                   7,576     7,503      7,555     7,534




    Effect of dilutive securities:

       Employee stock options                 76      --           84      --




    Weighted-average common and potential
       common shares outstanding
       (denominator for diluted earnings

       (loss) per share)                   7,652     7,503      7,639     7,534





    Basic earnings (loss) per share      $  0.15   $ (0.81)   $  0.47   $ (0.55)
                                         -------   -------    -------   -------


    Diluted earnings (loss) per share    $  0.15   $ (0.81)   $  0.47   $ (0.55)
                                         -------   -------    -------   -------


      Employee stock options for 1,462,000 and 701,000 shares for the three
      months ended September 30, 2000 and 1999, respectively, and 1,333,000 and
      465,000 shares for the nine months ended September 30, 2000 and 1999,
      respectively, were not included in the net earnings (loss) per share
      because their effect would have been anti-dilutive.


4.    COMPREHENSIVE INCOME (LOSS)
      ----------------------------



      The components of comprehensive income (loss) for the three months and
      nine months ended September 30, 2000 and 1999 are as follows:



                                       Three Months Ended     Nine Months Ended
                                          September 30          September 30
                                         (in thousands)        (in thousands)

                                        2000       1999        2000       1999
                                       -------    -------    -------    -------

    Net earnings (loss)                $ 1,174    $(6,066)   $ 3,580    $(4,133)
    Other comprehensive income (loss):
        Foreign currency translation      (108)       225       (266)       443
                                       -------    -------    -------    -------

    Total comprehensive income (loss)  $ 1,066    $(5,841)   $ 3,314    $(3,690)
                                       =======    =======    =======    =======


                                       -7-

<PAGE>




5.    SHAREHOLDERS' EQUITY
      --------------------

      As a result of stock options exercised on July 27, 2000, the excess of the
      cost of treasury shares over the exercise price of options exercised was
      recorded as a reduction of $752,000 to additional paid-in capital and a
      reduction of $828,000 to retained earnings. The income tax benefit from
      stock options exercised was $625,000 and $501,000 for the nine months
      ended September 30, 2000 and September 30, 1999, respectively. The benefit
      was recorded as an increase to additional paid-in capital.



6.    SEGMENT INFORMATION
      -------------------

      The Company operates in two segments, Cosmetic and Pharmaceutical, that
      have been organized by the products and services they offer. The Cosmetic
      segment's principal products are nail care, nail color, color cosmetics,
      beauty implements, bleaches and depilatories, personal care products and
      other related cosmetic items. The Pharmaceutical segment's principal
      products are proprietary oral analgesics, acne treatment products and
      first aid products. The accounting policies of the segments are the same
      as those described in the summary of significant accounting policies. The
      Company evaluates the performance of its operating segments based on
      operating income. Certain assets, including property, plant and equipment
      and deferred tax assets, are not allocated to the identifiable segments;
      depreciation of unallocated assets are charged to the Cosmetic segment.


                                  Three Months Ended        Nine Months Ended
                                      September 30             September 30
                                     (in thousands)           (in thousands)
                                    2000      1999            2000       1999
                                    ----      ----            ----       ----

Net sales
          Cosmetic               $  59,961   $  48,403    $ 172,867   $ 149,902
          Pharmaceutical            17,692      16,183       48,855      46,997
                                 ---------   ---------    ---------   ---------
          Consolidated           $  77,653   $  64,586    $ 221,722   $ 196,899
                                 =========   =========    =========   =========

Operating income (loss)
          Cosmetic               $     310   $ (10,307)   $   3,882   $ (10,034)

          Pharmaceutical             3,887       2,856        8,172       6,788
                                 ---------   ---------    ---------   ---------
          Consolidated           $   4,197   $  (7,451)   $  12,054   $  (3,246)
                                 =========   =========    =========   =========

Gain on asset sale               $    --     $    --      $     362   $   1,734

Interest expense, net                2,042       1,512        6,113       4,229
                                 ---------   ---------    ---------   ---------
Earnings  (Loss) before taxes    $   2,155   $  (8,963)   $   6,303   $  (5,741)
                                 =========   =========    =========   =========

Depreciation and amortization
          Cosmetic               $   1,844   $   1,681    $   5,223   $   4,838
          Pharmaceutical               121         114          350         329
                                 ---------   ---------    ---------   ---------
          Consolidated           $   1,965   $   1,795    $   5,573   $   5,167
                                 =========   =========    =========   =========









                                       -8-

<PAGE>



7.    SUPPLEMENTAL CASH FLOW INFORMATION
      ----------------------------------

      On February 22, 2000, the Company purchased a 68,000 square foot
      manufacturing, warehousing and office facility in Barrie, Ontario for
      $1,828,000. The purchase was financed with a combination of a mortgage
      bridge loan and a five-year mortgage. The mortgage bridge loan was repaid
      on April 3, 2000.

      Interest of $6,300,000 and $4,300,000, and income taxes of $1,700,000 and
      $700,000 were paid in the nine months ended September 30, 2000 and
      September 30, 1999, respectively. Income tax refunds of $2,200,000 related
      to taxes paid in 1999 were received in the nine months ended September 30,
      2000.



8.    GAIN ON SALE OF FACILITY

      On April 3, 2000, the Company sold a 39,000 square foot manufacturing,
      warehousing and office facility in Barrie, Ontario, with a net book value
      of approximately $442,000 for net proceeds of approximately $804,000.
      Approximately $640,000 of the proceeds was used to satisfy a mortgage
      bridge loan on its new facility in Barrie, Ontario purchased on February
      22, 2000.



9.    LONG-TERM DEBT
      --------------

      On April 26, 2000, the Company refinanced its purchase money promissory
      note of $3,822,000 for its property in North Carolina with a five-year
      $4,523,000 mortgage on the land and buildings. The mortgage includes an
      interest rate based on LIBOR and terms that provide for the maintenance of
      certain financial ratios.










                                       -9-

<PAGE>


Item 2.Management's Discussion and Analysis of Financial Condition and Results
       of Operations

(1)   RESULTS OF OPERATIONS
      ---------------------

      SECOND QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2000 VERSUS
      SEPTEMBER 30, 1999
      ---------------------------------------------------------------

      NET SALES
      ---------

      Net sales for the third quarter of 2000 were $77.7 million, an increase of
      20% compared to $64.6 million in 1999. Net sales for the first nine months
      of 2000 were $221.7 million, an increase of 12.6% compared to $196.9
      million in 1999.

      Cosmetic net sales for the third quarter of 2000 were $60.0 million, an
      increase of 23.9% compared to $48.4 million in 1999. Cosmetic net sales
      for the first nine months of 2000 were $172.9 million, an increase of
      15.3% compared to $149.9 million in 1999. The increase is due primarily to
      volume growth in the Sally Hansen family and N.Y.C. New York Color brands,
      together with lower product returns.

      Pharmaceutical net sales for the third quarter of 2000 were $17.7 million,
      an increase of 9.3% compared to $16.2 million in 1999. Pharmaceutical net
      sales for the first nine months of 2000 were $48.9 million, an increase of
      4.0% compared to $47.0 million in 1999. The increase is due primarily to
      volume growth in the Orajel brand and the Dermarest Psoriasis brand
      launched earlier in the year.


      COST OF GOODS SOLD
      ------------------

      Cost of goods sold in the third quarter of 2000 were $34.8 million, or
      44.8% of net sales, as compared to $34.7 million, or 53.8% of net sales in
      1999. Cost of goods sold for the first nine months of 2000 were $98.1
      million, or 44.3% of net sales, as compared to $93.2 million, or 47.4% of
      net sales in 1999. The decrease in cost of sales as a percentage of net
      sales is primarily attributable to lower product returns. Additionally,
      the third quarter of 1999 included an increase of $4.5 million in the
      inventory valuation reserve to reflect the estimated market value of the
      Naturistics inventory pursuant to the Company's plan to reduce excess and
      slow moving inventory of such brands.


      SELLING AND ADMINISTRATIVE EXPENSES
      -----------------------------------

      Selling and administrative expenses for the third quarter of 2000 were
      $38.6 million, or 49.8% of net sales, as compared to $37.3 million, or
      57.7% of net sales in 1999. Selling and administrative expenses for the
      first nine months of 2000 were $111.6 million, or 50.3% of net sales, as
      compared to $106.9 million, or 54.3% of net sales in 1999. The decrease in
      selling and administrative expenses, as a percentage of net sales, is
      primarily attributable to expenses increasing at a lower rate than the
      increase in net sales.

      GAIN ON SALE OF FACILITY
      ------------------------

      On April 3, 2000, the Company sold a 39,000 square foot manufacturing,
      warehousing and office facility in Barrie, Ontario, with a net book value
      of approximately $442,000, for net proceeds of approximately $804,000.


      NET INTEREST EXPENSE
      --------------------

      Interest expense, net of interest income, for the third quarter of 2000
      was $2.0 million, compared to $1.5 million in 1999. Interest expense, net
      of interest income for the first nine months of 2000 was $6.1 million,
      compared to $4.2 million in 1999. The increases are due to higher average
      borrowings for working capital requirements in 2000, in addition to
      increased borrowing rates, as compared to 1999.



                                      -10-

<PAGE>


      INCOME TAXES
      ------------

      Income taxes are based on the Company's expected annual effective tax rate
      of 43% in 2000 compared to an estimated 28% tax benefit in 1999.

      NET EARNINGS
      ------------

      Net earnings for the third quarter of 2000 were $1.2 million, compared to
      a prior year net loss of $6.1 million. Net earnings for the first nine
      months of 2000 were $3.6 million, compared to a prior year net loss of
      $4.1 million.




(2)   LIQUIDITY AND CAPITAL RESOURCES
      -------------------------------

      At September 30, 2000 the Company had cash and cash equivalents of $3.3
      million compared to $2.5 million at September 30, 1999.

      Net cash used in operating activities was $1.2 million for the nine months
      ended September 30, 2000 primarily due to an increase in accounts
      receivable of $12.5 million, principally due to the timing of increased
      shipments in the third quarter, partially offset by increases of $3.2
      million in accrued liabilities and $2.9 million in income taxes payable /
      receivable.

      Cash used for property, plant and equipment additions was $4.4 million for
      the nine months ended September 30, 2000 compared to $4.9 million in 1999.

      Net cash provided by financing activities for the nine months ended
      September 30, 2000 was $4.5 million due to proceeds received under the
      Company's revolving credit agreement and short-term borrowings under a
      line of credit with a bank, partially offset by repayments of short-term
      borrowings and principal payments of long-term debt.

      On April 3, 2000, the Company sold a 39,000 square foot manufacturing,
      warehousing and office facility in Barrie, Ontario, with a net book value
      of approximately $442,000 for net proceeds of approximately $804,000.
      Approximately $640,000 of the proceeds was used to satisfy a mortgage
      bridge loan on its new facility in Barrie, Ontario purchased on February
      22, 2000.

      On April 26, 2000, the Company refinanced its purchase money promissory
      note of $3,822,000 for its property in North Carolina with five-year
      $4,523,000 mortgage on the land and buildings. The mortgage includes an
      interest rate based on LIBOR and terms that provide for the maintenance of
      certain financial ratios.

      The Company believes that cash from future operations, cash on hand and
      amounts available from the credit facility, will be sufficient to satisfy
      its liquidity needs for the foreseeable future.









                                      -11-


<PAGE>




      NEW ACCOUNTING PRONOUNCEMENTS
      -----------------------------

      The Financial Accounting Standards Board issued Statement of Financial
      Accounting Standard No. 133, "Accounting for Derivative Instruments and
      Hedging Activities" (SFAS No. 133) as amended by SFAS 137 and SFAS 138,
      which is effective for quarters of fiscal years beginning after June 15,
      2000. SFAS No. 133 provides guidance for accounting for all derivative
      instruments, including certain derivative instruments embedded in other
      contracts, and for hedging activities. The Company does not believe that
      the implementation of SFAS No. 133 will have a significant impact on its
      financial position or results of operations.

      In May 2000, the Emerging Issues Task Force issued EITF 00-14 "Accounting
      for Certain Sales Incentives". The issue addresses the recognition,
      measurement and income statement classification for sales incentives
      offered voluntarily by a vendor, without charge, to customers that can be
      used in, or that are exercisable by a customer as a result of a single
      exchange transaction. Implementation of the EITF is required in the fourth
      quarter of fiscal 2000. Management has determined that implementation of
      EITF 00-14 will result in the reclassification of certain selling costs
      from selling and administrative expenses to net sales and is in the
      process of quantifying the amount of such reclassification.






      FORWARD - LOOKING STATEMENTS
      ----------------------------

      Management's Discussion and Analysis of the Results of Operations and
      Financial Condition and other sections of this Form 10-Q include
      "forward-looking statements" within the meaning of Section 27A of the
      Securities Act of 1933 and Section 21E of the Securities and Exchange Act
      of 1934 (the "Exchange Act"). All statements other than statements of
      historical information provided herein are forward-looking statements and
      may contain information about financial results, economic conditions,
      trends and known uncertainties. The forward-looking statements contained
      herein are subject to certain risks and uncertainties that could cause
      actual results to differ materially from those reflected in the
      forward-looking statements. Factors that might cause such a difference
      include, but are not limited to, delays in introducing new products or
      failure of consumers to accept new products, actions by competitors which
      may result in mergers, technology improvement or new product
      introductions, the dependence on certain national chain drug stores and
      mass merchandiser relationships due to the concentration of sales
      generated by such chains, changes in fashion oriented color cosmetics
      trends, and trends in the general economy.

      Readers are cautioned not to place undue reliance on these forward-looking
      statements, which reflect management's analysis, judgment, belief or
      expectation only as of the date hereof. The Company undertakes no
      obligation to publicly revise these forward-looking statements to reflect
      events or circumstances that arise after the date hereof. In addition to
      the disclosure contained herein, readers should carefully review any
      disclosure of risks and uncertainties contained in other documents the
      Company files or has filed from time to time with the Securities and
      Exchange Commission pursuant to the Exchange Act.











                                      -12-

<PAGE>








     PART II - OTHER INFORMATION








Item 6.     EXHIBITS AND REPORTS ON FORM 8-K
            --------------------------------

             (a) Exhibit 27.1  Financial Data Schedule


             (b) Reports on Form 8-K

                 None








                                      -13-



<PAGE>






                                   SIGNATURES
                                   ----------


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.




                                                DEL LABORATORIES, INC.
                                                ----------------------
                                                (Registrant)








 DATE: NOVEMBER 6, 2000                         /S/ DAN K. WASSONG
 ----------------------                         -----------------------
                                                Dan K. Wassong
                                                Chairman, President and
                                                Chief Executive Officer








 DATE: NOVEMBER 6, 2000                         /S/ ENZO J. VIALARDI
 ----------------------                         ------------------------------
                                                Enzo J. Vialardi
                                                Executive Vice President and
                                                Chief Financial Officer




















<PAGE>